1015 Lausanne, Switzerland, EPFL Innovation Park D
YugaCell provides specialized solutions in bioinformatics and machine learning.
We use domain expertise in large scale multiomics, single-cell sequencing, immune repertoire profiling, and artificial intelligence/statistics to tackle the most challenging R&D projects.
Cell Receptor Inc. has IP for improving results in oncological treatment by targeting upstream steps of growth signaling, not noticed in oncology yet. A well-tolerated affordable treatment of low toxicity! It will prevent metastasis in most cancers.www.nature.com/articles/d43747-021-00133-8
Using state of the art technologies, we aim at manufacturing kits for the analysis and editing of therapeutically relevant antibodies such as monoclonal antibodies effective against immunology disorders or oncology.Our kits for antibody genome sequencing and editing are based on the NGS method.